You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Optimized lactoferrin for treatment of intracerebral hemorrhage
SBC: Pharmareview Corporation Topic: NINDSDESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Ovarian cancer using novel nanoparticle formulations
SBC: KIROMIC BIOPHARMA INC Topic: 102DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New heterocyclic inhibitors of filoviruses
SBC: MICROBIOTIX, INC. Topic: HDESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New small molecule inhibitors of arenaviruses
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of monoclonal catalytic antibodies for HIV immunotherapy
SBC: COVALENT IMMUNOLOGY PRODUCTS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): We have raised murine monoclonal antibodies (MAbs) to a conserved region of the CD4 binding site of gp120 (CD4bs) that neutralize genetically diverse HIV strains. The MAbs have a novel mechanism of action. They hydrolyze multiple molecules of gp120, thereby imparting MAb increased biological efficacy. About 10% of HIV infected subjects develop resistance to cur ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Inhibition of Biofilms on Tympanostomy Tubes
SBC: SELENIUM LTD Topic: NIDCDDESCRIPTION (provided by applicant): Bacterial biofilm formation on medical implants is a serious clinical problem. Biofilms can turn a simple implant into a serious complication. Recently we showed that the covalent attachment of micrograms of organo-selenium to the surface of an orthodontic device will inhibit the formation of a biofilm without harmful side-effects. This has recently (2009) led ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Contractile Hydrogel Dressing for Primary Wound Closure
SBC: LYNNTECH INC. Topic: NIDDKDESCRIPTION (provided by applicant): Acute and chronic wounds such as diabetic foot ulcers represent a major area of medical concern. With roughly 27 million patients suffering from these types of partial thickness wounds, representing substantial billions in medical expenses, a means to rapidly close such acute and chronic wounds with minimal medical staff involvement would be a major new bre ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Planar Lightwave Circuit based Surface Enhanced Raman Scattering Spectrometer wit
SBC: OMEGA OPTICS, INC. Topic: NIBIBDESCRIPTION (provided by applicant): In this small business technology transfer research (STTR) program, Omega Optics and the University of Texas at Austin propose to develop a planar lightwave circuit based surface-enhanced Raman scattering (SERS) spectrometer for single molecule detection. The sensitivity of the SERS spectrometer comes from the 5-nm gap between gold nanowires, which can achieve ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Measuring and monitoring carbon nanotubes and their potential toxicity
SBC: Medical Nanotechnologies, Inc. Topic: NIEHSDESCRIPTION (provided by applicant): The Environmental Protection Agency (EPA) recently classified carbon nanotubes (CNTs) as a new chemical substance. Consequently, CNTs are now subject to regulatory controls that require inventory control, quantification of CNT amounts, and possibly toxicity tests. However, rapidly and inexpensively quantifying the CNTs in commercially available material and ass ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health